nodes	percent_of_prediction	percent_of_DWPC	metapath
Norepinephrine—ADRA1D—polycystic ovary syndrome	0.171	0.273	CbGaD
Norepinephrine—ADRB3—polycystic ovary syndrome	0.153	0.245	CbGaD
Norepinephrine—ADRA1B—polycystic ovary syndrome	0.146	0.233	CbGaD
Norepinephrine—SLC22A3—Metformin—polycystic ovary syndrome	0.111	0.475	CbGbCtD
Norepinephrine—ADRA1A—polycystic ovary syndrome	0.0981	0.157	CbGaD
Norepinephrine—SLC22A2—Metformin—polycystic ovary syndrome	0.0657	0.281	CbGbCtD
Norepinephrine—ADRB2—polycystic ovary syndrome	0.0583	0.0931	CbGaD
Norepinephrine—SLC22A1—Metformin—polycystic ovary syndrome	0.0571	0.244	CbGbCtD
Norepinephrine—SLC18A1—adrenal gland—polycystic ovary syndrome	0.00177	0.0629	CbGeAlD
Norepinephrine—SLC18A1—vagina—polycystic ovary syndrome	0.00164	0.0583	CbGeAlD
Norepinephrine—SLC18A1—endocrine gland—polycystic ovary syndrome	0.00153	0.0546	CbGeAlD
Norepinephrine—CYP1A2—urine—polycystic ovary syndrome	0.00139	0.0493	CbGeAlD
Norepinephrine—ADRB3—adipose tissue—polycystic ovary syndrome	0.00111	0.0393	CbGeAlD
Norepinephrine—PAH—endocrine gland—polycystic ovary syndrome	0.0011	0.0392	CbGeAlD
Norepinephrine—ADRB3—female gonad—polycystic ovary syndrome	0.000925	0.0329	CbGeAlD
Norepinephrine—SLC18A2—endometrium—polycystic ovary syndrome	0.000699	0.0249	CbGeAlD
Norepinephrine—SLC22A3—embryo—polycystic ovary syndrome	0.000681	0.0242	CbGeAlD
Norepinephrine—SLC18A2—uterus—polycystic ovary syndrome	0.000644	0.0229	CbGeAlD
Norepinephrine—SLC18A2—adipose tissue—polycystic ovary syndrome	0.00063	0.0224	CbGeAlD
Norepinephrine—SLC18A2—adrenal gland—polycystic ovary syndrome	0.000565	0.0201	CbGeAlD
Norepinephrine—Phenylephrine—ADRA1D—polycystic ovary syndrome	0.000532	0.102	CrCbGaD
Norepinephrine—SLC18A2—vagina—polycystic ovary syndrome	0.000524	0.0186	CbGeAlD
Norepinephrine—Arbutamine—ADRB3—polycystic ovary syndrome	0.000506	0.0968	CrCbGaD
Norepinephrine—SLC22A3—endometrium—polycystic ovary syndrome	0.000498	0.0177	CbGeAlD
Norepinephrine—SLC18A2—endocrine gland—polycystic ovary syndrome	0.00049	0.0174	CbGeAlD
Norepinephrine—ADRA1D—endocrine gland—polycystic ovary syndrome	0.000484	0.0172	CbGeAlD
Norepinephrine—SLC22A1—adipose tissue—polycystic ovary syndrome	0.00047	0.0167	CbGeAlD
Norepinephrine—Phenylephrine—ADRA1B—polycystic ovary syndrome	0.000454	0.0869	CrCbGaD
Norepinephrine—ADRB1—adipose tissue—polycystic ovary syndrome	0.000452	0.0161	CbGeAlD
Norepinephrine—SLC22A3—adipose tissue—polycystic ovary syndrome	0.000449	0.016	CbGeAlD
Norepinephrine—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000423	0.0151	CbGeAlD
Norepinephrine—SLC22A5—adrenal cortex—polycystic ovary syndrome	0.000406	0.0144	CbGeAlD
Norepinephrine—SLC22A3—adrenal gland—polycystic ovary syndrome	0.000403	0.0143	CbGeAlD
Norepinephrine—SLC22A1—vagina—polycystic ovary syndrome	0.00039	0.0139	CbGeAlD
Norepinephrine—ADRA2C—endometrium—polycystic ovary syndrome	0.000378	0.0134	CbGeAlD
Norepinephrine—SLC22A3—female gonad—polycystic ovary syndrome	0.000375	0.0134	CbGeAlD
Norepinephrine—SLC22A3—vagina—polycystic ovary syndrome	0.000373	0.0133	CbGeAlD
Norepinephrine—SLC22A1—endocrine gland—polycystic ovary syndrome	0.000365	0.013	CbGeAlD
Norepinephrine—SLC22A5—endometrium—polycystic ovary syndrome	0.000362	0.0129	CbGeAlD
Norepinephrine—ADRA1A—adipose tissue—polycystic ovary syndrome	0.000358	0.0127	CbGeAlD
Norepinephrine—DRD2—pituitary gland—polycystic ovary syndrome	0.000352	0.0125	CbGeAlD
Norepinephrine—ADRB1—endocrine gland—polycystic ovary syndrome	0.000352	0.0125	CbGeAlD
Norepinephrine—SLC22A3—endocrine gland—polycystic ovary syndrome	0.000349	0.0124	CbGeAlD
Norepinephrine—ADRA2C—uterus—polycystic ovary syndrome	0.000348	0.0124	CbGeAlD
Norepinephrine—SLC6A2—adrenal gland—polycystic ovary syndrome	0.000345	0.0123	CbGeAlD
Norepinephrine—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000342	0.0122	CbGeAlD
Norepinephrine—ADRA2C—adipose tissue—polycystic ovary syndrome	0.000341	0.0121	CbGeAlD
Norepinephrine—SLC22A5—pituitary gland—polycystic ovary syndrome	0.000328	0.0117	CbGeAlD
Norepinephrine—SLC22A5—adipose tissue—polycystic ovary syndrome	0.000326	0.0116	CbGeAlD
Norepinephrine—Droxidopa—ADRA1D—polycystic ovary syndrome	0.000324	0.0619	CrCbGaD
Norepinephrine—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000321	0.0114	CbGeAlD
Norepinephrine—Phenylephrine—ADRA1A—polycystic ovary syndrome	0.000306	0.0585	CrCbGaD
Norepinephrine—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000306	0.0109	CbGeAlD
Norepinephrine—ADRA2A—endometrium—polycystic ovary syndrome	0.000302	0.0107	CbGeAlD
Norepinephrine—SLC6A2—endocrine gland—polycystic ovary syndrome	0.000299	0.0106	CbGeAlD
Norepinephrine—SLC22A5—adrenal gland—polycystic ovary syndrome	0.000293	0.0104	CbGeAlD
Norepinephrine—Droxidopa—ADRB3—polycystic ovary syndrome	0.000291	0.0556	CrCbGaD
Norepinephrine—ADRA2C—female gonad—polycystic ovary syndrome	0.000285	0.0101	CbGeAlD
Norepinephrine—ADRA2C—vagina—polycystic ovary syndrome	0.000283	0.0101	CbGeAlD
Norepinephrine—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000278	0.00989	CbGeAlD
Norepinephrine—ADRA2A—uterus—polycystic ovary syndrome	0.000278	0.00989	CbGeAlD
Norepinephrine—Droxidopa—ADRA1B—polycystic ovary syndrome	0.000276	0.0528	CrCbGaD
Norepinephrine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000273	0.00971	CbGeAlD
Norepinephrine—SLC22A5—female gonad—polycystic ovary syndrome	0.000273	0.00971	CbGeAlD
Norepinephrine—DRD2—endocrine gland—polycystic ovary syndrome	0.000273	0.0097	CbGeAlD
Norepinephrine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000272	0.00967	CbGeAlD
Norepinephrine—SLC22A5—vagina—polycystic ovary syndrome	0.000271	0.00965	CbGeAlD
Norepinephrine—Isoprenaline—ADRB3—polycystic ovary syndrome	0.000264	0.0506	CrCbGaD
Norepinephrine—Levonordefrin—ADRA1A—polycystic ovary syndrome	0.000264	0.0505	CrCbGaD
Norepinephrine—Epinephrine—ADRA1D—polycystic ovary syndrome	0.000247	0.0473	CrCbGaD
Norepinephrine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000244	0.00867	CbGeAlD
Norepinephrine—Isoetarine—ADRB2—polycystic ovary syndrome	0.000242	0.0463	CrCbGaD
Norepinephrine—CYP1A2—endocrine gland—polycystic ovary syndrome	0.00023	0.00818	CbGeAlD
Norepinephrine—ADRA2A—female gonad—polycystic ovary syndrome	0.000227	0.00809	CbGeAlD
Norepinephrine—ADRA2A—vagina—polycystic ovary syndrome	0.000226	0.00804	CbGeAlD
Norepinephrine—Epinephrine—ADRB3—polycystic ovary syndrome	0.000222	0.0425	CrCbGaD
Norepinephrine—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000211	0.00752	CbGeAlD
Norepinephrine—Epinephrine—ADRA1B—polycystic ovary syndrome	0.000211	0.0403	CrCbGaD
Norepinephrine—Arbutamine—ADRB2—polycystic ovary syndrome	0.000193	0.0368	CrCbGaD
Norepinephrine—Salbutamol—ADRB2—polycystic ovary syndrome	0.000187	0.0357	CrCbGaD
Norepinephrine—Droxidopa—ADRA1A—polycystic ovary syndrome	0.000186	0.0356	CrCbGaD
Norepinephrine—Epinephrine—ADRA1A—polycystic ovary syndrome	0.000142	0.0272	CrCbGaD
Norepinephrine—Droxidopa—ADRB2—polycystic ovary syndrome	0.000111	0.0211	CrCbGaD
Norepinephrine—Isoprenaline—ADRB2—polycystic ovary syndrome	0.000101	0.0192	CrCbGaD
Norepinephrine—Isoprenaline—CYP1A1—polycystic ovary syndrome	8.62e-05	0.0165	CrCbGaD
Norepinephrine—Epinephrine—ADRB2—polycystic ovary syndrome	8.45e-05	0.0162	CrCbGaD
Norepinephrine—ADRA2B—Signaling by GPCR—POMC—polycystic ovary syndrome	4.7e-06	4.42e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—INS—polycystic ovary syndrome	4.69e-06	4.41e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—PRL—polycystic ovary syndrome	4.69e-06	4.41e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	4.68e-06	4.41e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	4.67e-06	4.39e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.67e-06	4.39e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.65e-06	4.37e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	4.64e-06	4.36e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	4.63e-06	4.35e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—GNAS—polycystic ovary syndrome	4.6e-06	4.33e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.59e-06	4.32e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—TH—polycystic ovary syndrome	4.58e-06	4.31e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.57e-06	4.3e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—GNAS—polycystic ovary syndrome	4.57e-06	4.29e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.56e-06	4.29e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—PLAT—polycystic ovary syndrome	4.55e-06	4.28e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—GHRL—polycystic ovary syndrome	4.55e-06	4.28e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—IGF1—polycystic ovary syndrome	4.54e-06	4.27e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—AKT2—polycystic ovary syndrome	4.54e-06	4.27e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.52e-06	4.25e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—NCOR1—polycystic ovary syndrome	4.51e-06	4.24e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	4.5e-06	4.23e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.49e-06	4.22e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	4.47e-06	4.2e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.46e-06	4.19e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	4.46e-06	4.19e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.45e-06	4.18e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	4.43e-06	4.16e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—NGFR—polycystic ovary syndrome	4.42e-06	4.15e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	4.42e-06	4.15e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—GNAS—polycystic ovary syndrome	4.41e-06	4.15e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—POMC—polycystic ovary syndrome	4.39e-06	4.13e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—NCOR1—polycystic ovary syndrome	4.39e-06	4.13e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—PLAT—polycystic ovary syndrome	4.39e-06	4.12e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—GHRL—polycystic ovary syndrome	4.39e-06	4.12e-05	CbGpPWpGaD
Norepinephrine—DRD2—GPCR downstream signaling—POMC—polycystic ovary syndrome	4.38e-06	4.12e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	4.38e-06	4.12e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—PRL—polycystic ovary syndrome	4.38e-06	4.12e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.35e-06	4.09e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—NGFR—polycystic ovary syndrome	4.35e-06	4.09e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—ATF1—polycystic ovary syndrome	4.34e-06	4.08e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—POMC—polycystic ovary syndrome	4.32e-06	4.06e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.31e-06	4.05e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—PRL—polycystic ovary syndrome	4.31e-06	4.05e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—CYP1A1—polycystic ovary syndrome	4.28e-06	4.02e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—NRG1—polycystic ovary syndrome	4.27e-06	4.02e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.23e-06	3.98e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	4.22e-06	3.97e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.22e-06	3.97e-05	CbGpPWpGaD
Norepinephrine—DRD2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.21e-06	3.96e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—NCOR1—polycystic ovary syndrome	4.2e-06	3.95e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	4.19e-06	3.94e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	4.19e-06	3.94e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—ATF1—polycystic ovary syndrome	4.18e-06	3.94e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	4.16e-06	3.91e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—CYP1A1—polycystic ovary syndrome	4.16e-06	3.91e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.15e-06	3.91e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.15e-06	3.91e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—GNAS—polycystic ovary syndrome	4.12e-06	3.88e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.09e-06	3.84e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.08e-06	3.84e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	4.07e-06	3.83e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	4.07e-06	3.83e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	4.07e-06	3.83e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	4.07e-06	3.83e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.06e-06	3.82e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	4.01e-06	3.77e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—MTHFR—polycystic ovary syndrome	3.99e-06	3.75e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—CYP1A1—polycystic ovary syndrome	3.98e-06	3.75e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	3.98e-06	3.75e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	3.98e-06	3.75e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	3.97e-06	3.74e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.96e-06	3.73e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.93e-06	3.69e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	3.93e-06	3.69e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	3.9e-06	3.67e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	3.89e-06	3.66e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	3.89e-06	3.66e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	3.88e-06	3.65e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.88e-06	3.65e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—NGFR—polycystic ovary syndrome	3.86e-06	3.63e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	3.86e-06	3.63e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—NRG1—polycystic ovary syndrome	3.85e-06	3.63e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	3.85e-06	3.62e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—POMC—polycystic ovary syndrome	3.84e-06	3.61e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	3.83e-06	3.6e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—PRL—polycystic ovary syndrome	3.83e-06	3.6e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.8e-06	3.58e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	3.79e-06	3.57e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—GNAS—polycystic ovary syndrome	3.79e-06	3.56e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	3.77e-06	3.55e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.77e-06	3.54e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	3.74e-06	3.52e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—MTHFR—polycystic ovary syndrome	3.71e-06	3.49e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	3.69e-06	3.47e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.67e-06	3.45e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—IRS2—polycystic ovary syndrome	3.66e-06	3.44e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.63e-06	3.41e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.61e-06	3.4e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	3.6e-06	3.39e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	3.59e-06	3.37e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—LEP—polycystic ovary syndrome	3.58e-06	3.37e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	3.56e-06	3.35e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	3.56e-06	3.35e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	3.56e-06	3.34e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	3.55e-06	3.34e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—NRG1—polycystic ovary syndrome	3.54e-06	3.33e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	3.49e-06	3.29e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling by GPCR—IL6—polycystic ovary syndrome	3.47e-06	3.27e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	3.44e-06	3.23e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	3.43e-06	3.22e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	3.38e-06	3.18e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.37e-06	3.17e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.37e-06	3.17e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.33e-06	3.13e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.33e-06	3.13e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	3.31e-06	3.12e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	3.3e-06	3.11e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.27e-06	3.07e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	3.26e-06	3.07e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.26e-06	3.07e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—PPARG—polycystic ovary syndrome	3.23e-06	3.04e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	3.23e-06	3.04e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.21e-06	3.02e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—IRS1—polycystic ovary syndrome	3.19e-06	3e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	3.19e-06	3e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—POMC—polycystic ovary syndrome	3.19e-06	3e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	3.18e-06	2.99e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—INS—polycystic ovary syndrome	3.17e-06	2.98e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.16e-06	2.98e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	3.15e-06	2.96e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.15e-06	2.96e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	3.14e-06	2.96e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	3.14e-06	2.96e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.13e-06	2.94e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.12e-06	2.94e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	3.1e-06	2.92e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	3.08e-06	2.9e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—INS—polycystic ovary syndrome	3.08e-06	2.9e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—POMC—polycystic ovary syndrome	3.07e-06	2.89e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—INS—polycystic ovary syndrome	3.06e-06	2.88e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	3.03e-06	2.85e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.02e-06	2.84e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—PPARG—polycystic ovary syndrome	3.01e-06	2.83e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.98e-06	2.8e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—POMC—polycystic ovary syndrome	2.97e-06	2.79e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	2.97e-06	2.79e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	2.97e-06	2.79e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.96e-06	2.79e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—IGF1—polycystic ovary syndrome	2.96e-06	2.78e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—AKT2—polycystic ovary syndrome	2.95e-06	2.78e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—INS—polycystic ovary syndrome	2.95e-06	2.78e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	2.92e-06	2.75e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	2.92e-06	2.75e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.91e-06	2.74e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.88e-06	2.71e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.85e-06	2.68e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.81e-06	2.64e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	2.8e-06	2.63e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.8e-06	2.63e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	2.79e-06	2.62e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	2.78e-06	2.61e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	2.76e-06	2.6e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	2.74e-06	2.58e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	2.74e-06	2.58e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	2.72e-06	2.56e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.7e-06	2.54e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.69e-06	2.53e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.69e-06	2.53e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	2.69e-06	2.53e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.67e-06	2.51e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.67e-06	2.51e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	2.65e-06	2.49e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	2.64e-06	2.48e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.64e-06	2.48e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.63e-06	2.48e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	2.59e-06	2.44e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	2.58e-06	2.43e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.56e-06	2.41e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	2.55e-06	2.4e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	2.55e-06	2.4e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	2.54e-06	2.39e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.54e-06	2.38e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—TH—polycystic ovary syndrome	2.53e-06	2.38e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	2.52e-06	2.37e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.5e-06	2.36e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	2.5e-06	2.36e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.5e-06	2.35e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.49e-06	2.35e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.49e-06	2.34e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	2.46e-06	2.31e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.45e-06	2.31e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.45e-06	2.31e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	2.45e-06	2.31e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.44e-06	2.3e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.37e-06	2.23e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.35e-06	2.21e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	2.35e-06	2.21e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	2.34e-06	2.2e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.33e-06	2.19e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	2.31e-06	2.18e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.27e-06	2.13e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.26e-06	2.13e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling by GPCR—IL6—polycystic ovary syndrome	2.26e-06	2.13e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.26e-06	2.13e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	2.25e-06	2.12e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.19e-06	2.06e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.18e-06	2.05e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.18e-06	2.05e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.15e-06	2.02e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.11e-06	1.98e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	2.09e-06	1.97e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.07e-06	1.95e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	2.06e-06	1.94e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.06e-06	1.94e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—IL6—polycystic ovary syndrome	2.05e-06	1.93e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.04e-06	1.92e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.03e-06	1.91e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.02e-06	1.9e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.02e-06	1.9e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	1.97e-06	1.85e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.93e-06	1.82e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.92e-06	1.81e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	1.91e-06	1.79e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	1.88e-06	1.77e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.86e-06	1.75e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.76e-06	1.66e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.74e-06	1.64e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.74e-06	1.64e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.73e-06	1.63e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.72e-06	1.62e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.67e-06	1.57e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.63e-06	1.53e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.6e-06	1.51e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.55e-06	1.46e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.48e-06	1.39e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.42e-06	1.34e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.41e-06	1.33e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.39e-06	1.31e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.38e-06	1.3e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—IL6—polycystic ovary syndrome	1.34e-06	1.26e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.32e-06	1.24e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	1.22e-06	1.14e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.21e-06	1.13e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	1.19e-06	1.12e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.13e-06	1.06e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	1.02e-06	9.61e-06	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	9.85e-07	9.26e-06	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	9.15e-07	8.61e-06	CbGpPWpGaD
